NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

Prospectus approval and publication

The prospectus regarding the Rights Issue has been approved and registered by the Swedish Financial Supervisory Authority and is now available on the Company's website (http://investors.scibase.se/en) and on Vator Securities' website (www.vatorsecurities.se). The prospectus will also be available on the Swedish Financial Supervisory Authority's website (www.fi.se).

Rights Issue preliminary timeline

May 7, 2020                            Record date for participation in the Rights Issue with pre-emptive rights, that is, shareholders who are registered in the Company's share register as of this day will receive unit rights for participation in the Rights Issue with pre-emptive rights

May 11 - 22, 2020                 Trading in unit rights (trading in paid subscribed units will commence on the same date and continue until the Rights Issue has been registered with the Swedish Companies Registration Office)

May 11 - 26, 2020                 Subscription period (with or without pre-emptive rights)

Around May 28, 2020            Announcement of the outcome of the Rights Issue

Around June 5, 2020             The Rights Issue is completed and registered

Advisors

Vator Securities is financial advisor and Setterwalls Advokatbyrå is legal adviser to SciBase in connection with the Rights Issue.

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com

Certified Advisor:
Avanza
Tel: +46
409 421 20
Email: corp@avanza.se

The information was submitted, through the agency of the contact person set out above, for publication at the time stated by Scibase's news distributor Cision upon publication of this press release.About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed and sells a unique point-of-care device for evaluation of skin disorders such as skin cancer and atopic dermatitis. Its first product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and inflammation. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies and abnormalities. SciBase is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

Important information

Publication, distribution or release of this release can in some jurisdictions be subject to restrictions by law and persons in those jurisdictions where this release has been published or distributed should inform themselves of and comply with such legal restrictions. The recipient of this release is responsible to use this release and information herein in accordance with applicable rules in respective jurisdiction. This release does not contain or constitute an offer, nor an invitation, to acquire or subscribe for shares or other securities in the Company in any jurisdiction, either from the Company or from any others.

The information in this release may not be distributed or sent into Australia, Canada, Hong Kong, Japan, New Zealand, Switzerland, Singapore, South Africa the United States or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. Acts in contrary to this instruction can constitute a crime according to applicable securities laws. This release is not an offer or invitation to acquire or subscribe for shares or other securities in the United States. The securities that have been mentioned in this release are not allowed to be sold in the United States without registration, or without application of an exemption from registration, according to the applicable U.S. Securities Act from 1933 ("Securities Act"), or as a part of a transaction that is not covered by the registration requirements according to the Securities Act. There is no intention to register any shares or securities mentioned herein in the United States or to announce a public offering of such securities in the United States.

This release is not a prospectus in accordance with the definition in the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation"). Complete information regarding the rights issue can only be obtained through the prospectus which has been published. Pursuant to article 2 k of the Prospectus Regulation, this press release constitutes an advertisement.

This information is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "Relevant Persons"). This information must not be acted on or relied upon by persons who are not Relevant Persons. An investment or an investment activity referred to in this release is only available in the United Kingdom for Relevant Persons and will only be conducted with Relevant Persons.

This release may include forward-looking statements. Forward looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and beyond the Company's control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.

Information to distributors

For the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) national implementing measures, (together the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the offered shares have been subject to a product approval process, who have established that these shares are: (i) suitable for a target marked consisting of non-professional investors and investors who fulfil the criteria for professional clients and eligible counterparties, each as defined in MiFID II, and (ii) suitable for distribution through all distribution channels that has been approved in MiFID II ("Target Market Assessment"). Irrespective of the Target Market Assessment, distributors should note that: the price of the shares in the Company may decline and investors could lose all or part of their investment; the Company's shares offer no guaranteed income and no capital protection; and an investment in the Company's shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The target market assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the issues.

The target market assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, purchase, or take any other action whatsoever with respect to the Company's shares.

Each distributor is responsible for undertaking its own target market assessment in respect of the Company's shares and determining appropriate distribution channels.

Stockholm, Sweden - SciBase (SCIB) announced today, on "Melanoma Monday", that they have entered into a collaboration agreement with Advanced Dermatology and Cosmetic Surgery ("ADCS") - the premier dermatology network in the US with over 150 practices. The agreement will provide ADCS practices with Nevisense, the only FDA approved melanoma detection system, for the analysis of patients' atypical moles at point-of-care.

 The partnership further supports ADCS's commitment to the early detection of skin cancer, and their goal of integrating evidence-based technology solutions that help deliver the best possible care to their patients.  SciBase will initially install Nevisense in 20 clinics to evaluate practice workflow integration, followed by expansion within ADCS's large network of practices. The practices will be supplied with the latest product, Nevisense 3.0, which received FDA approval on April 30th. ADCS and SciBase will also collaborate on scientific research and the evaluation of new products addressing other skin conditions.

"We are excited to integrate Nevisense during routine total body skin cancer exams to offer our patients the most advanced technology for the earliest possible detection of melanoma.  Melanoma is the deadliest form of skin cancer, but when detected early, treatment has a nearly 100% cure rate.  Early testing and treatment are critical for improving survival.  Providing our patients with enhanced technology for early testing further supports our continued commitment to delivering best in class care that elevates both our provider and patient experience" said Dr. Matt Leavitt, Chief Executive Officer and Founder of Advanced Dermatology and Cosmetic Surgery.

"Having the nation's largest dermatology practice network adopt Nevisense and offer patients advanced care options is an important milestone in our strategy to increase our US focus and broaden our presence in the US market" said Simon Grant, Chief Executive Officer of SciBase.  "The collaboration also validates the clinical value we can provide with Nevisense and is a reflection of the growing acceptance we see from providers to adopt AI-based healthcare solutions that are supported by solid clinical evidence and can improve patient care."

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com


Certified Advisor: 
Avanza
Tel:
+46 8 409 421 20
Email: corpt@avanza.se

About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed and sells a unique point-of-care device for evaluation of skin disorders such as skin cancer and atopic dermatitis. Its first product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and inflammation. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies and abnormalities. SciBase is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

ABOUT Advanced Dermatology and Cosmetic Surgery

Advanced Dermatology and Cosmetic Surgery is the largest dermatology practice in the country. We are committed to providing comprehensive and unparalleled dermatologic and aesthetic care in a welcoming and engaging environment, seeking to make each patient experience unique. We strive to combine the best of the art of medicine with the latest advances in research and technology in formulating individualized treatment plans to achieve the desired result with superior patient safety and privacy standards.

To learn more about Advanced Dermatology, visit www.advancedderm.com or call 1-866-400-DERM.

SciBase (SCIB) Stockholm, Sweden - announced today that it has received approval from the US Food and Drug Administration (FDA) for Nevisense 3.0, the third generation of their Nevisense system for early melanoma detection. Nevisense, an AI-based point-of-care system for the non-invasive evaluation of irregular moles remains the only FDA approved system available for melanoma detection in the US.

Nevisense 3.0 is a more efficient and streamlined version of the product previously approved by the FDA. The  European version released at the end of 2018 has significantly improved both adoption and utilization, and has been used clinically on over 30,000 patients to date.

"The release of Nevisense 3.0 in late 2018 in Germany and the EU has been the catalyst for five consecutive quarters of growth, and we see this as step one of our strategic plan" said Simon Grant, Chief Executive Officer of SciBase. "Receiving US approval means that we can focus on step two of our strategy which is to increase our marketing and sales activities in the US based on our deep market experience with Nevisense 3.0 in Germany and the positioning we have developed for Nevisense in the US.'

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com


Certified Advisor:
Avanza
Tel: +
46 8 409 421 20
Email: corp@avanza.se 

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12.45 CET on May 1, 2020.

About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed and sells a unique point-of-care device for evaluation of skin disorders such as skin cancer and atopic dermatitis. Its first product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and inflammation. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies and abnormalities. SciBase is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

SciBase AI based developments and solutions are seen as being on the forefront, and are covered in the AI Company Peltarion’s Blog: “Can a pen from the future change the lives for millions of children with eczema, asthma and allergies?”

Please follow the link to read the story: https://peltarion.com/blog/applied-ai/scibase

Today, an extraordinary general meeting has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved, in accordance with the proposals presented in the notice to attend the meeting (which is available on the Company's website www.scibase.com):

(i)                 To change the articles of association and reduce the share capital without cancellation of shares.

(ii)               To approve the board of directors' resolution on issuance of units consisting of shares and warrants with preferential rights for the shareholders (the "Rights Issue").

(iii)              To change the articles of association and increase the share capital through bonus issue without issuance of new shares.

(iv)              To reduce the share capital without cancellation of shares.

(v)               To change the articles of association and reduce the share capital without cancellation of shares subject to authorization from the Swedish Companies Registration Office or a general court. 

  

Resolutions in accordance with item (i)-(iv) above were proposed in order to enable the Rights Issue resolved by the board of directors subject to the subsequent approval of the general meeting, to minimize the subsequent increase of the share capital and to adjust the limits of the share capital and the number of shares in the articles of association, to be registered simultaneously. Resolution in accordance with item (v) above was presented in order to enable further reduction of the share capital following registration of the other proposals, with the main purpose of decreasing the quotient value in order to enable a subscription price within the range for the new shares that may be subscribed for through exercise of the warrants issued in the Rights Issue and in order to otherwise adapt the capital structure.

The Rights Issue in short

The Rights Issue consists of up to 19,941,721 units with a subscription price of SEK 1.25 per unit. Each unit consists of one (1) share and one (1) warrant.

The record date for obtaining unit rights and to participate in the Rights Issue with pre-emptive rights will be Thursday, May 7, 2020. Each existing share in the Company will entitle to six (6) unit rights and five (5) unit rights will entitle to subscription of one (1) unit.

In the event that not all units are subscribed for by exercise of unit rights in accordance with the shareholders' pre-emptive rights, the board shall, within the framework of the maximum amount for the Rights Issue, resolve on allotment of units subscribed for without unit rights.

The warrants are issued free of charge and will be exercisable for subscription of new shares during the period October 5 - October 16, 2020. Each warrant will entitle the holder to subscribe for one (1) new share in the Company at an exercise price corresponding to the higher of (i) 70 per cent of the volume-weighted average price of the Company's share on Nasdaq First North Growth Market during a period of ten (10) trading days immediately preceding September 30, 2020 (including September 30, 2020), but not less than SEK 1 and not more than SEK 1.75 per share, and (ii) the quotient value of the share at the time the warrants are exercised.

The Rights Issue is fully covered by subscription undertakings and guarantee commitments. Neither subscription undertakings nor guarantee commitments are secured through bank guarantee, blocked funds, pledge or similar arrangements.

For more information, please refer to the press release published by the Company on March 26, 2020 (which is available on the Company's website www.scibase.com).

Full terms and conditions for the Rights Issue will be disclosed in the EU Growth Prospectus which will be published by the Company no later than in conjunction with the commencement of the subscription period.

Rights Issue preliminary timelines

May 5, 2020     Last day of trading including unit rights

May 6, 2020     First day of trading excluding unit rights

May 7, 2020                                      Record date for participation in the Rights Issue with pre-emptive rights, that is, shareholders who are registered in the Company's share register as of this day will receive unit rights for participation in the Rights Issue with pre-emptive rights

May 11 - 22, 2020                         Trading in unit rights (trading in paid subscribed units will commence on the same date and continue until the issue has been registered with the Swedish Companies Registration Office)

May 11 - 26, 2020                         Subscription period (with or without pre-emptive rights)

Around May 28, 2020                  Announcement of the outcome of the Rights Issue

Around June 5, 2020                    The Rights Issue is completed and registered

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com

Certified Advisor (CA):

Avanza

Tel: +46 8 409 421 20

Email: corp@avanza.se

The information was submitted for publication, through the agency of the contact person set out above, on April 29, 2020 at 11.00 CET.

About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed and sells a unique point-of-care device for evaluation of skin disorders such as skin cancer and atopic dermatitis. Its first product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and inflammation. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies and abnormalities. SciBase is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

Important information

Publication, distribution or release of this release can in some jurisdictions be subject to restrictions by law and persons in those jurisdictions where this release has been published or distributed should inform themselves of and comply with such legal restrictions. The recipient of this release is responsible to use this release and information herein in accordance with applicable rules in respective jurisdiction. This release does not contain or constitute an offer, nor an invitation, to acquire or subscribe for shares or other securities in the Company in any jurisdiction, either from the Company or from any others.

The information in this release may not be distributed or sent into Australia, Canada, Hong Kong, Japan, New Zealand, Switzerland, Singapore, South Africa the United States or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. Acts in contrary to this instruction can constitute a crime according to applicable securities laws. This release is not an offer or invitation to acquire or subscribe for shares or other securities in the United States. The securities that have been mentioned in this release are not allowed to be sold in the United States without registration, or without application of an exemption from registration, according to the applicable U.S. Securities Act from 1933 ("Securities Act"), or as a part of a transaction that is not covered by the registration requirements according to the Securities Act. There is no intention to register any shares or securities mentioned herein in the United States or to announce a public offering of such securities in the United States.

This release is not a prospectus in accordance with the definition in the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation"). Complete information regarding the rights issue can only be obtained through the prospectus expected to be publicized. Pursuant to article 2 k of the Prospectus Regulation, this press release constitutes an advertisement.

This information is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "Relevant Persons"). This information must not be acted on or relied upon by persons who are not Relevant Persons. An investment or an investment activity referred to in this release is only available in the United Kingdom for Relevant Persons and will only be conducted with Relevant Persons.

This release may include forward-looking statements. Forward looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and beyond the Company's control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.

Information to distributors

For the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) national implementing measures, (together the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the offered shares have been subject to a product approval process, who have established that these shares are: (i) suitable for a target marked consisting of non-professional investors and investors who fulfil the criteria for professional clients and eligible counterparties, each as defined in MiFID II, and (ii) suitable for distribution through all distribution channels that has been approved in MiFID II ("Target Market Assessment"). Irrespective of the Target Market Assessment, distributors should note that: the price of the shares in the Company may decline and investors could lose all or part of their investment; the Company's shares offer no guaranteed income and no capital protection; and an investment in the Company's shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The target market assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the issues.

The target market assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, purchase, or take any other action whatsoever with respect to the Company's shares.

Each distributor is responsible for undertaking its own target market assessment in respect of the Company's shares and determining appropriate distribution channels.

SPECIAL PROCEDURE DUE TO THE SPREAD OF CORONAVIRUS

In light of the spread of the coronavirus, the board of directors has decided to implement certain precautionary measures for the extraordinary general meeting on 29 April 2020 in order to ascertain the well-being of the company’s shareholders’ as well as the opportunity for them to exercise their rights at the general meeting.

The Public Health Agency of Sweden has made the assessment that the risk for spread of the virus is very high and recommend avoidance of large gatherings and crowds. If one cannot avoid large gatherings, any time spent in such a situation should be kept at a minimum. For this reason, the timeframe for the general meeting will be kept a minimum, without restricting the shareholders’ rights. No food or beverage will be served in connection with the general meeting and representatives of the board of directors and the senior management of the company will not attend physically, but only through telephone.

Voting by proxy

Considering the current situation, the shareholders are asked to consider the possibility not to attend the meeting in person and instead attend by proxy. The Swedish Parliament has adopted a temporary legislation, which from 15 April 2020 provides Swedish limited companies increased possibilities to collect proxies to facilitate general meetings. With support of this temporary legislation, the board of directors of SciBase Holding AB (publ) has resolved to provide the shareholders with a special proxy form for exercise of voting rights. Instead of attending the general meeting in person, a shareholder may use the proxy form to authorize representatives of SciBase Holding AB (publ) and Setterwalls Advokatbyrå AB to vote for their shares at the general meeting in accordance with the shareholder’s instructions. The proxy form can be downloaded http://investors.scibase.se/en/extra-general-meeting-april-29-2020.

The consequences of the Covid19 outbreak have started to affect SciBase from mid-March, and there is a high risk that these could lead to a significant financial impact on the Group. However, the effects are very difficult to predict, and the situation is constantly changing.

First and foremost, we at SciBase are working to ensure that the business continues to operate to the best of our ability, but also with a focus of our employees’ health. Practically speaking, this entails (among other things), a call for the company’s employees to work from home and a travel ban.

The immediate, visible effects are that some of our most important conferences and meetings have been canceled or moved forward, and this has already had a negative effect on, and will continue to affect our sales over the coming period. It has become more difficult to hold physical customer meetings, and we are working to transfer these to virtual (video) or telephone meetings.

Given the uncertain situation at present, it is not possible to estimate the full potential impact for SciBase.

We continue to work together with our partners, customers and employees to handle this extraordinary situation in the best possible way.

A pdf-version of the annual report is enclosed to this press-release.

A printed version of the Annual report will only be distributed to shareholders who actively request a printed copy.

For more information, please contact:

Michael Colérus, CFO Tel: +46 70 341 34 72 E-mail: michael.colerus@scibase.com

Certified Advisor: Avanza Tel: +46 409 421 20 Email: corp@avanza.se

The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on April 3, 2020.

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed and sells a unique point-of-care device for evaluation of skin disorders such as skin cancer and atopic dermatitis. Its first product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and inflammation. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies and abnormalities. SciBase is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

Download the Annual Report 2019

SciBase Holding AB ("SciBase" or the "Company") has updated the Company's financial calendar for 2020.
 

Due to the preparation of the rights issue announced earlier today, the Company has resolved on changes in the Company's financial calendar. The Company's annual report in respect of the financial year 2019 will be made public on April 3, 2020, the interim report in respect of the first quarter of 2020 will be made public on May 5, 2020 and the annual general meeting will be held on June 17, 2020.

The updated financial calendar is set out as follows:

 

April 3                                             Annual report 2019

May 5                                              Interim report Q1 2020

June 17                                          Annual general meeting 2020

August 20                                      Interim report Q2 2020

November 12                                 Interim report Q3 2020

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com

Certified Advisor (CA):

Avanza

Tel: +46 8 409 421 20

Email: corp@avanza.se

About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed and sells a unique point-of-care device for evaluation of skin disorders such as skin cancer and atopic dermatitis. Its first product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and inflammation. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies and abnormalities. SciBase is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

Notice

Shareholders who wish to attend the meeting must be recorded in the share register kept by Euroclear Sweden AB on the record date which is Thursday, April 23, 2020, and notify the company of their intention to attend no later than the same day (i.e. Thursday, April 23, 2020.) Notice of attendance is made in writing to SciBase Holding AB (publ), P.O. Box 3337, SE-103 67 Stockholm, Sweden, or by e-mail to info@scibase.com or by phone to +46 8 410 620 00. The notice of attendance shall include name, personal or corporate ID number, address and phone number. The same dates, addresses, and formal requirements apply for notifying the company of any accompanying advisors. Powers of attorneys, certificates of incorporation and other documents of authorization must be presented at the meeting, but can preferably be sent to the company in connection with the notice of attendance.

Shareholders whose shares are registered in the names of nominees must temporarily register the shares in their own name in order to be entitled to attend the meeting (so called voting registration). In order for such voting registration to be completed as per Thursday, April 23, 2020 the shareholders must inform their nominees well before this date.

A shareholder's rights at the meeting may be exercised by a proxy empowered by a power of attorney. The power of attorney shall be in writing, dated and signed and must not be older than five years. The original power of attorney must be presented at the meeting. Those representing a legal person must also present a certificate of registration or similar, evidencing the authorized signatories. A proxy form is available on the company's website, www.scibase.com.

For information regarding how your personal data is processed in connection with the meeting, please refer to the privacy policy on Euroclear Sweden AB's website, https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Proposed agenda
 

  1. Opening of the meeting
  2. Election of Chairman of the meeting
  3. Drawing up and approval of the voting list
  4. Approval of the agenda
  5. Election of one or two persons to verify the minutes
  6. Determination as to whether the meeting has been duly convened
  7. Resolutions regarding changes to the articles of association and reduction of the share capital without cancellation of shares
  8. Resolution regarding approval of the board of directors' resolution on issuance of units consisting of shares and warrants with preferential rights for the shareholders
  9. Resolution regarding changes to the articles of association and an increase of the share capital through bonus issue without issuance of new shares
  10. Resolution regarding a reduction of the share capital without cancellation of shares
  11. Resolution regarding changes to the articles of association and reduction of the share capital without cancellation of shares subject to authorization from the Swedish Companies Registration Office or a general court 
  12. Closing of the meeting

Proposed resolutions

The board of directors has presented the following proposals to be resolved at the extraordinary general meeting. The board of directors' proposals in accordance with items 7-10 are presented in order to enable the rights issue resolved by the board of directors subject to the subsequent approval of the general meeting, to minimize the subsequent increase of the share capital and to adjust the limits of the share capital and the number of shares in the articles of association, to be registered simultaneously. The board of directors' proposal in accordance with item 11 has been presented in order to, subject to authorization from the Swedish Companies Registration Office or a general court, enable further reduction of the share capital following registration of the other proposals, with the main purpose of decreasing the quotient value in order to enable a subscription price within the range for the new shares that may be subscribed for through exercise of the warrants issued in the rights issue and in order to otherwise adapt the capital structure.

Item 7. Resolutions regarding changes to the articles of association and reduction of the share capital without cancellation of shares

The board of directors proposes that the meeting resolves on (i) changes to the articles of association and (ii) reduction of the share capital without cancellation of shares in accordance with the below. The proposals have been presented in order to enable the rights issue that is proposed to be approved in accordance with item 8 on the proposed agenda. The proposals shall be deemed as one proposal and therefore be adopted by the meeting as the same resolution.

  1. Changes to the articles of association

The board of directors proposes that the meeting resolves on changes to the limits of the share capital and the number of shares in sections 4 and 5 in the articles of association.

The board of directors proposes that the wording of section 4 in the articles of association is revised from "The share capital shall be no less than SEK 18,000,000 and no more than SEK 72,000,000" to "The share capital shall be no less than SEK 1,600,000 and no more than SEK 6,400,000".

The board of directors proposes that the wording of section 5 in the articles of association is revised from "The number of shares shall be no less than 4,900,000 and no more than 19,600,000" to "The number of shares shall be no less than 16,000,000 and no more than 64,000,000".

  1. Reduction of the share capital without cancellation of shares

The board of directors proposes that the meeting resolves on reduction of the share capital without cancellation of shares. The share capital shall be reduced by SEK 59,825,163.6. The purpose of the reduction is transfer to non-restricted equity.

Following the reduction, the company's share capital will amount to SEK 1,661,810.1 divided among 16,618,101 shares (before registration of the rights issue). The reduction will entail that the quotient value of the share is changed from SEK 3.7 to SEK 0.1 per share.

The proposed reduction requires changes to the articles of association and is conditional upon that an increase of the share capital is carried out(including changes to the articles of association) whereby the share capital is restored, i.e. with an amount corresponding to no less than the reduction. The reduction of the share capital will thus be admissible without authorization from the Swedish Companies Registration Office or a general court.

Miscellaneous

Resolutions in accordance with (i) - (ii) above shall be conditional upon the meeting also resolving in accordance with items 8 and 9 on the proposed agenda.

The Chairman of the board of directors, the CEO, or anyone appointed by the board of directors shall have the right to make any minor adjustments required to register the resolution.

A valid resolution in accordance with this proposal requires that the proposal is supported by shareholders representing at least two-thirds (2/3) of the votes cast and the shares represented at the meeting.

Item 8. Resolution regarding approval of the board of directors' resolution on issuance of units consisting of shares and warrants with preferential rights for the shareholders

The board of directors proposes that the meeting resolves to approve the board of directors' resolution on issuance of so called units, in the form of new shares and warrants giving right to subscribe for new shares, with preferential rights for the shareholders in accordance with the below.

Number of units and share capital increase

The issue comprises no more than 19,941,721 new shares and no more than 19,941,721 warrants, which may only be subscribed for and allotted together in the form of so called units where each unit consists of one (1) share and one (1) warrant. After the issue, the shares and the warrants will be separated. Each warrant entitles to subscription of one (1) new share in the company.

The company's share capital may be increased through subscription of the new shares and through exercise of the warrants for subscription of new shares. The company's share capital may be increased by no more than SEK 3,988,344.20, out of which SEK 1,994,172.10 is from the new shares and SEK 1,994,172.10 is from the new shares that may be subscribed for through exercise of the warrants. The share capital increases have been calculated based on a quotient value of SEK 0.10 per share (after registration of the reduction of the share capital as proposed in accordance with the previous item on the proposed agenda). The share capital increase may however be smaller with regard to the part that is emanating from the exercise of the warrants, due to the proposal regarding further decrease of the share capital in accordance with the last item on the proposed agenda. If authorization for reduction is obtained and registered before the warrants are exercised for subscription for new shares, the increase in share capital will in this part instead be no more than SEK 997,086.05, based on a quotient value of SEK 0.05 per share.

Right to subscribe for units

Those who on the record date are registered as holders of shares in the CSD register kept by Euroclear Sweden AB are entitled to subscribe for units with preferential rights. The record date for receipt of subscription rights and a right to participate in the issue with preferential rights shall be Thursday, May 7, 2020. Each share entitles to six (6) subscription rights and five (5) subscription rights entitles to subscription of one (1) unit.

Subscription may also take place without subscription rights. In the event that not all units are subscribed for by exercise of subscription rights, the board of directors shall, within the framework of the maximum amount for the issue, resolve on allotment of units to those who have subscribed without subscription rights in accordance with the following principles:

- Firstly, allotment of unit that have been subscribed for without subscription rights is to be made to those who have subscribed for units by exercise of subscription rights, irrespective of whether the subscriber was holder of shares on the record date or not and, in the event of oversubscription, pro rata in relation to the number of subscription rights that have been exercised for subscription of units and, to the extent not possible, by drawing of lots.

- Secondly, allotment of units that have been subscribed for without subscription rights is to be made to those who have subscribed for units without exercise of subscription rights, irrespective of whether the subscriber was holder of shares on the record date or not and, in the event of oversubscription, pro rata in relation to the number of units for which each of them have applied for subscription and, to the extent not possible, by drawing of lots.

- Thirdly and lastly, allotment of shares is to be made to those who have entered into guarantee commitments in capacity of guarantors and, in the event of oversubscription, pro rata in relation to the number of units for which each of them have guaranteed subscription and, to the extent not possible, by drawing of lots.

Subscription price of units

The subscription price for a unit shall amount to SEK 1.25 and refers to the share. The warrants are issued free of charge.

Subscription and payment of units

Subscription of units, with or without exercise of subscription rights, is to take place during the period from May 11, 2020 until and including May 26, 2020.

Subscription through exercise of subscription rights shall be made by simultaneous cash payment to an account designated by the company during the period from May 11, 2020 until and including May 26, 2020.

Subscription of units without subscription rights shall be made on a special application list. Payment for units subscribed for without exercise of subscription rights is to be made to an account designated by the company not later than three (3) banking days after notice of allotment.

The board of directors shall have the right to prolong the period for subscription and payment.

To the extent deemed appropriate by the board of directors, and provided that it may take place without detriment to the company or its creditors, the board of directors may allow payment by way of set-off in accordance with Chapter 13 Section 41 of the Swedish Companies Act.

Subscription and subscription price of new shares subscribed for through exercise of warrants

Subscription of new shares through exercise of warrants may be made during the period from and including October 5, 2020 up to and including October 16, 2020.

Each warrant entitle the holder to subscribe for one (1) new share in the company at a subscription price per share (the "Exercise Price") corresponding to the higher of (i) 70 percent of the volume weighted average trading price of the company's share on Nasdaq First North Growth Market during a period of 10 trading days immediately preceding September 30, 2020 (September 30, 2020 included), however no less than SEK 1.00 and no more than SEK 1.75 per share, and (ii) the quotient value of the share at the time of exercise of warrants. If no trading price is recorded for a particular trading day within the specified period, such day shall not be taken into account, but the period shall instead be extended backwards in time with the number of previous trading days required for the period to comprise a total of 10 trading days with a recorded trading price. The Exercise Price calculated in accordance with item (i) above shall be rounded off to two decimals, where SEK 0,005 shall be rounded upwards.

Other terms and conditions for the warrants

The warrants are also subject to the terms and conditions, including customary terms and conditions for recalculation, stated in the board of directors' complete resolution.

Right to dividends of new shares

The new shares shall entitle to dividends as from the first time on the record date for dividend occurring after the shares have been registered with the Swedish Companies Registration Office and entered in the share register kept by Euroclear Sweden AB.

Conditions

The resolution requires and is conditional upon the meeting also resolving to reduce the share capital (including changes to the articles of association) resulting in that the quotient value of the share correspond to no more than the subscription price of new shares and its registration is conditional upon that the issuance fit within the limits of the articles of association.

Miscellaneous

The Chairman of the board of directors, the CEO, or anyone appointed by the board of directors shall have the right to make any minor adjustments required to register the resolution.

The resolution is valid only subject to subsequent approval of the meeting by support of shareholders representing more than half of the votes cast.

Item 9. Resolution regarding changes to the articles of association and an increase of the share capital through bonus issue without issuance of new shares

The board of directors proposes that the meeting resolves on (i) changes to the articles of association and (ii) an increase of the share capital through a bonus issue without issuance of new shares in accordance with the below. The proposals are presented in order to enable the reduction of the share capital in accordance with item 7 on the proposed agenda without requiring authorization from the Swedish Companies Registration Office or a general court. The proposals shall be deemed as one proposal and therefore be adopted by the meeting as the same resolution.

  1. Changes to the articles of association

In order to enable an increase of the share capital through a bonus issue and also to adjust the limits with respect to the different resolutions proposed to the meeting, the board of directors proposes that the meeting resolves on changes to the limits of the share capital and the number of shares in sections 4 and 5 in the articles of association.

The board of directors proposes that the wording of section 4 in the articles of association is revised from "The share capital shall be no less than SEK 1,600,000 and no more than SEK 6,400,000" (after registration of the changes to the articles of association in accordance with item 7 on the proposed agenda) to "The share capital shall be no less than SEK 60,000,000 and no more than SEK 240,000,000".

The board of directors proposes that the wording of section 5 in the articles of association is revised from "The number of shares shall be no less than 16,000,000 and no more than 64,000,000" (after registration of the changes to the articles of association in accordance with item 7 on the proposed agenda) to "The number of shares shall be no less than 30,000,000 and no more than 120,000,000".

  1. Increase of the share capital through a bonus issue without issuance of new shares

The board of directors proposes that the meeting resolves on an increase of the share capital through a bonus issue without issuance of new shares. The share capital shall be increased by the amount of SEK 59,825,163.6. The bonus issue shall be carried out through transfer of the corresponding amount from non-restricted equity to share capital.

The increase is conducted in order to enable the proposed reduction of the share capital in accordance with item 7 on the proposed agenda without authorization from the Swedish Companies Registration Office or a general court. The increase will entail that the quotient value of the share is changed from SEK 0.1 (after registration of the proposed reduction of the share capital) to a higher amount which is dependent upon the increase of the share capital through the rights issue as well as the additional reduction of the share capital that is proposed in the next item on the proposed agenda.

The proposed increase requires changes to the articles of association and is conditional upon a reduction of the share capital (including changes to the articles of association) with a corresponding amount.

Miscellaneous

Resolutions in accordance with (i) - (ii) above is conditional upon the meeting also resolving in accordance with item 7 on the proposed agenda.

The Chairman of the board of directors, the CEO, or anyone appointed by the board of directors shall have the right to make any minor adjustments required to register the resolution.

A valid resolution in accordance with this proposal requires that the proposal is supported by shareholders representing at least two-thirds (2/3) of the votes cast and the shares represented at the meeting.

Item 10. Resolution regarding a reduction of the share capital without cancellation of shares

The board of directors proposes that the general meeting resolves on a reduction of the share capital without cancellation of shares in accordance with the below. The proposal has been presented in order to minimize the share capital increase resulting from the previous items on the proposed agenda.

The board of directors proposes that the general meeting resolves on a reduction of the share capital without cancellation of shares. The share capital shall be reduced by an amount of no more than SEK 1,994,172.1 (in accordance with the below). The purpose of the reduction is transfer to non-restricted equity.

The reduction of the share capital shall be determined to an amount in SEK corresponding to the increase of the share capital resulting from the registration of the new shares that are issued as part of the units (i.e. excluding such new shares that may be subscribed for through exercise of the warrants) in the rights issue in accordance with item 8 on the proposed agenda, not exceeding SEK 1,994,172.1, adjusted downwards (if applicable) to the amount that entail that the quotient value of the share, after completion of the reduction, will be an amount in SEK with no more than two decimals. The latter adjustment should only be made if the share's quotient value, after the reduction, would have three or more decimals.

The reduction is carried out so that the resolutions set forth in the previous items on the proposed agenda, combined, shall not increase the company's share capital or restricted equity (other than due to such adjustment of the reduction amount required to obtain an appropriate quotient value in accordance with the above). The reduction will entail that the quotient value of the share is adjusted downwards after registration of the previous resolution on the proposed agenda.

The proposed reduction is conditional upon that an increase of the share capital (including changes to the articles of association) as a result of which the share capital is restored, i.e. with an amount at least corresponding to the reduction, is carried out. The reduction of the share capital will thus be admissible without authorization from the Swedish Companies Registration Office or a general court.

The resolution shall be conditional upon the meeting also resolving in accordance with items 7-9 on the proposed agenda.

The Chairman of the board of directors, the CEO, or anyone appointed by the board of directors shall have the right to make any minor adjustments required to register the resolution.

A valid resolution in accordance with this proposal requires that the proposal is supported by shareholders representing at least two-thirds (2/3) of the votes cast and the shares represented at the meeting.

Item 11. Resolution regarding changes to the articles of association and reduction of the share capital without cancellation of shares subject to authorization from the Swedish Companies Registration Office or a general court 

The board of directors proposes that the meeting resolves on (i) changes to the articles of association and (ii) reduction of the share capital without cancellation of shares in accordance with the below. The proposals have been presented in order to enable further reduction of the share capital, subject to authorization from the Swedish Companies Registration Office or a general court, after registration of the other matters on the proposed agenda. The main purpose is to decrease the quotient value in order to enable a subscription price within the range for the new shares that may be subscribed for through exercise of the warrants that are issued as part of the rights issue. The increase is also proposed in order to otherwise adapt the capital structure. The proposals shall be deemed as one proposal and therefore be adopted by the meeting as the same resolution.

  1. Changes to the articles of association

The board of directors proposes that the wording of section 4 in the articles of association is revised from "The share capital shall be no less than SEK 60,000,000 and no more than SEK 240,000,000" (after registration of the changes to the articles of association in accordance with item 9 on the proposed agenda) to "The share capital shall be no less than SEK 1,500,000 and no more than SEK 6,000,000".

  1. Reduction of the share capital without cancellation of shares

The board of directors proposes that the general meeting resolves on a reduction of the share capital without cancellation of shares. The share capital shall be reduced by an amount of no more than SEK 60,024,580.82 (in accordance with the below). The purpose of the reduction is transfer to non-restricted equity.

The reduction of the share capital shall be determined to an amount in SEK resulting in a quotient value of the company's shares of SEK 0.05 (after registration of the other resolutions on the proposed agenda). The exact amount is thus dependent on the share capital changes resulting from the other resolutions on the proposed agenda but shall never exceed SEK 60,024,580.82 (out of which SEK 365,598.22 of the maximum amount refer to the highest possible adjustment amount at reduction of the share capital according to item 10 on the proposed agenda and shall only result in reduction according to this proposal, to the extent that the reduction amount becomes lower than the highest possible amount for the reduction carried out according to item 10), implying that the proposed reduction will result in that the company's share capital will amount to SEK 1,827,991.1 after the reduction, provided that the rights issue in accordance with item 8 on the proposed agenda is fully subscribed and that the reduction is registered before any further changes of the share capital (for example as a result of subscription for shares through exercise of the warrants issued in the rights issue).

The proposed resolution requires changes to the articles of association and is conditional upon that an authorization is obtained from the Swedish Companies Registration Office or a general court. 

Miscellaneous

Resolutions in accordance with (i) - (ii) above is conditional upon the meeting also resolving in accordance with the previous items on the proposed agenda.

The Chairman of the board of directors, the CEO, or anyone appointed by the board of directors shall have the right to make any minor adjustments required to register the resolution.

A valid resolution in accordance with this proposal requires that the proposal is supported by shareholders representing at least two-thirds (2/3) of the votes cast and the shares represented at the meeting.

 

Information at the meeting

Pursuant to Chapter 7 Section 32 of the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)) the board of directors and the CEO are obliged to, if any shareholder so requests and the board of directors deems that it can be done without significant harm to the company, provide information in respect of any circumstances which may affect the assessment of an item on the agenda.

Number of shares and votes

At the time of the issuance of this notice, the total number of shares and votes in the company amounted to 16,618,101.

Documentation

The board of director's resolutions on issuance, complete proposals and documentation in accordance with Chapter 12 Section 7, Chapter 13 Section 6, Chapter 14 Section 8 and Chapter 20 Sections 13-14 of the Swedish Companies Act will be available at the company's office and at the company's website www.scibase.com no later than two weeks before the meeting. Copies of the aforementioned documentation will also be sent by post free of charge to shareholders who so request and provide their postal address.

_____

Stockholm, March 2020

The board of directors

For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com

Certified Advisor (CA):

Avanza

Tel: +46 8 409 421 20

Email: corp@avanza.se

About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed and sells a unique point-of-care device for evaluation of skin disorders such as skin cancer and atopic dermatitis. Its first product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and inflammation. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies and abnormalities. SciBase is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.